(New) The pharmaceutical composition according to claim 153, wherein said substance is a monoclonal antibody reactive to CTGF.

## **REMARKS**

Claims 104-154 are now pending in this application. The newly added claims 104-154 are supported in originally pending, now canceled claims 1-82.

No new matter has been added.

In the event any fees are due in connection with the filing of this preliminary amendment or attached application or if petitions are required, applicants petition for any required relief and authorize the Commissioner to charge the cost of such petitions or other fees to our Deposit Account No. 50-0815.

> Respectfully submitted, **BOZICEVIC, FIELD & FRANCIS LLP**

> > Registration No. 28,807

**BOZICEVIC, FIELD & FRANCIS LLP** 

200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400

Facsimile: (650) 327-3231

F:\DOCUMENT\SHIM (Shimizu, formerly SHI)\006\pre amend 2.doc